Show simple item record

dc.contributor.authorMarson, Justin
dc.contributor.authorLitchman, Graham
dc.contributor.authorSvoboda, Ryan
dc.contributor.authorGlazer, Alex
dc.contributor.authorFarberg, Aaron
dc.contributor.authorWinkelmann, Richard
dc.contributor.authorRigel, Darrell
dc.date.accessioned2023-03-03T19:48:36Z
dc.date.available2023-03-03T19:48:36Z
dc.date.issued2021-03-06
dc.identifier.citationMarson, J., Litchman, G., Svoboda, R., Glazer, A., Farberg, A., Winkelmann, R., & Rigel, D. (2021). Assessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferences. SKIN The Journal of Cutaneous Medicine, 5(2), 101–107. DOI: 10.25251/skin.5.2.4en_US
dc.identifier.eissn2574-1624
dc.identifier.doi10.25251/skin.5.2.4
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8486
dc.description.abstractBackground: The 31-gene expression profile (31-GEP) test uses 31 genetic markers obtained from the initial biopsy of a melanoma to assess melanoma-specific survival and sentinel lymph node positivity. Objective: To assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists. Methods: Data from 589 unique dermatologists were collected during 2 virtual, nation-wide dermatology conferences via an 18-question survey on practice demographics and their clinical use and opinion of the 31-GEP test. Results: Participants reported that integrating the 31-GEP test may benefit patients by increasing knowledge and understanding (72.5%), personalizing treatment options (58.8%), and easing uncertainty about the future (59.7%). Benefits of using the 31-GEP test included identifying true negative patients in high-risk populations (65.6%) as well as true positives in low-risk populations (70.6%).A majority of participants also noted that if a patient received a 31-GEP Class 2B result, they would escalate subsequent management even if the lesions were classified as T1 (61.4%) or AJCC8 Stage I (59.0%). 84.9% of participants were somewhat to very likely to use 31-GEP testing for patient management or recommend this test to a colleague. Limitations: Potential respondent-selection and recall bias. Conclusion: Dermatologists are increasingly integrating the 31-GEP test into their melanoma clinical management decisions. As the 31-GEP test becomes more prevalent in practice, patients may benefit from decreased anxiety and uncertainty from enhanced prognosis, decreased need for unwarranted procedures such as sentinel lymph node biopsy and optimized allocation of healthcare resources.en_US
dc.language.isoN/Aen_US
dc.publisherNational Society for Cutaneous Medicineen_US
dc.relation.urlhttps://jofskin.org/index.php/skin/article/view/1203en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMelanomaen_US
dc.subjectPigmented Lesions,en_US
dc.subject31-Gene Expression Profileen_US
dc.subjectPrognosisen_US
dc.subjectSurveyen_US
dc.titleAssessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferencesen_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleSKIN The Journal of Cutaneous Medicineen_US
dc.source.volume5
dc.source.issue2
dc.source.beginpage101
dc.source.endpage107
dc.description.versionVoRen_US
refterms.dateFOA2023-03-03T19:48:36Z
dc.description.institutionSUNY Downstateen_US
dc.description.departmentDermatologyen_US
dc.description.degreelevelN/Aen_US


Files in this item

Thumbnail
Name:
1203-Article Text-6221-1-10-20 ...
Size:
331.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International